Christoph P Hornik1, Daniel K Benjamin2, P Brian Smith2, Michael J Pencina3, Adriana H Tremoulet4, Edmund V Capparelli5, Jessica E Ericson6, Reese H Clark7, Michael Cohen-Wolkowiez2. 1. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Department of Pediatrics, Duke University School of Medicine, Durham, NC. Electronic address: christoph.hornik@duke.edu. 2. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Department of Pediatrics, Duke University School of Medicine, Durham, NC. 3. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC. 4. Department of Pediatrics, University of California, San Diego, La Jolla, CA. 5. Deparment of Biostatistics and Bioinformatics, Duke University, Durham, NC; Skaggs School of Pharmacy, University of California, San Diego, La Jolla, CA. 6. Department of Pediatrics, Penn State University, Hershey, PA. 7. Pediatrix-Obstetrix Center for Research and Education, Sunrise, FL.
Abstract
OBJECTIVE: To evaluate the relationship between ampicillin dosing, exposure, and seizures. STUDY DESIGN: This was a retrospective observational cohort study of electronic health record (EHR) data combined with pharmacokinetic model derived drug exposure predictions. We used the EHR from 348 Pediatrix Medical Group neonatal intensive care units from 1997 to 2012. We included all infants 24-41 weeks gestational age, 500-5400 g birth weight, first exposed to ampicillin prior to 25 days postnatal age. Using a 1-compartment pharmacokinetic model and EHR data, we simulated maximum ampicillin concentration at steady state (Cmaxss, µg/mL) and area under the concentration time curve from 0 to 24 hours (AUC24, µg*h/dL). Using multivariable logistic regression, we evaluated association between ampicillin dosing, exposure, and seizures as documented in the EHR. RESULTS: We identified 131 723 infants receiving 134 041 courses of ampicillin for 653 506 infant-days of exposure. The median daily dose was 200 mg/kg/d (25th, 75th percentile; 100, 200). Median Cmaxss and AUC24 were 256.6 µg/mL (164.3, 291.5) and 2593 µg*h/dL (1917, 3334). On multivariable analysis, dosing was not associated with seizures. However increasing Cmaxss (OR = 1.10, 95% CI 1.03, 1.17) and AUC24 (OR 1.11, 95% CI 1.05, 1.18) were associated with increased odds of seizures. CONCLUSIONS: In this cohort of hospitalized infants, higher ampicillin exposure was associated with seizures as documented in the EHR.
OBJECTIVE: To evaluate the relationship between ampicillin dosing, exposure, and seizures. STUDY DESIGN: This was a retrospective observational cohort study of electronic health record (EHR) data combined with pharmacokinetic model derived drug exposure predictions. We used the EHR from 348 Pediatrix Medical Group neonatal intensive care units from 1997 to 2012. We included all infants 24-41 weeks gestational age, 500-5400 g birth weight, first exposed to ampicillin prior to 25 days postnatal age. Using a 1-compartment pharmacokinetic model and EHR data, we simulated maximum ampicillin concentration at steady state (Cmaxss, µg/mL) and area under the concentration time curve from 0 to 24 hours (AUC24, µg*h/dL). Using multivariable logistic regression, we evaluated association between ampicillin dosing, exposure, and seizures as documented in the EHR. RESULTS: We identified 131 723 infants receiving 134 041 courses of ampicillin for 653 506 infant-days of exposure. The median daily dose was 200 mg/kg/d (25th, 75th percentile; 100, 200). Median Cmaxss and AUC24 were 256.6 µg/mL (164.3, 291.5) and 2593 µg*h/dL (1917, 3334). On multivariable analysis, dosing was not associated with seizures. However increasing Cmaxss (OR = 1.10, 95% CI 1.03, 1.17) and AUC24 (OR 1.11, 95% CI 1.05, 1.18) were associated with increased odds of seizures. CONCLUSIONS: In this cohort of hospitalized infants, higher ampicillin exposure was associated with seizures as documented in the EHR.
Authors: Julia Dunne; William J Rodriguez; M Dianne Murphy; B Nhi Beasley; Gilbert J Burckart; Jane D Filie; Linda L Lewis; Hari C Sachs; Philip H Sheridan; Peter Starke; Lynne P Yao Journal: Pediatrics Date: 2011-10-24 Impact factor: 7.124
Authors: Barbara J Stoll; Nellie I Hansen; Rosemary D Higgins; Avroy A Fanaroff; Shahnaz Duara; Ronald Goldberg; Abbot Laptook; Michelle Walsh; William Oh; Ellen Hale Journal: Pediatr Infect Dis J Date: 2005-07 Impact factor: 2.129
Authors: B J Stoll; T Gordon; S B Korones; S Shankaran; J E Tyson; C R Bauer; A A Fanaroff; J A Lemons; E F Donovan; W Oh; D K Stevenson; R A Ehrenkranz; L A Papile; J Verter; L L Wright Journal: J Pediatr Date: 1996-07 Impact factor: 4.406
Authors: Michael Cohen-Wolkowiez; Brenda Poindexter; Margarita Bidegain; Joern-Hendrik Weitkamp; Robert L Schelonka; David A Randolph; Robert M Ward; Kelly Wade; Gloria Valencia; David Burchfield; Antonio Arrieta; Varsha Mehta; Michele Walsh; Anand Kantak; Maynard Rasmussen; Janice E Sullivan; Neil Finer; Wade Rich; Beverly S Brozanski; John van den Anker; Jeffrey Blumer; Matthew Laughon; Kevin M Watt; Gregory L Kearns; Edmund V Capparelli; Karen Martz; Katherine Berezny; Daniel K Benjamin; P Brian Smith Journal: Clin Infect Dis Date: 2012-09-05 Impact factor: 9.079
Authors: Adriana Tremoulet; Jennifer Le; Brenda Poindexter; Janice E Sullivan; Matthew Laughon; Paula Delmore; Andrea Salgado; Sandy Ian-U Chong; Chiara Melloni; Jamie Gao; Daniel K Benjamin; Edmund V Capparelli; Michael Cohen-Wolkowiez Journal: Antimicrob Agents Chemother Date: 2014-03-10 Impact factor: 5.938
Authors: Christoph P Hornik; Andrew M Atz; Catherine Bendel; Francis Chan; Kevin Downes; Robert Grundmeier; Ben Fogel; Debbie Gipson; Matthew Laughon; Michael Miller; Michael Smith; Chad Livingston; Cindy Kluchar; Anne Heath; Chanda Jarrett; Brian McKerlie; Hetalkumar Patel; Christina Hunter Journal: Appl Clin Inform Date: 2019-05-08 Impact factor: 2.342
Authors: Christine A Olson; Helen E Vuong; Jessica M Yano; Qingxing Y Liang; David J Nusbaum; Elaine Y Hsiao Journal: Cell Date: 2018-05-24 Impact factor: 41.582
Authors: Sara Salerno; Christoph P Hornik; Michael Cohen-Wolkowiez; P Brian Smith; Lawrence C Ku; Matthew S Kelly; Reese Clark; Daniel Gonzalez Journal: Pediatr Infect Dis J Date: 2017-09 Impact factor: 3.806
Authors: Rachel G Greenberg; Huali Wu; Anil Maharaj; Michael Cohen-Wolkowiez; Kay M Tomashek; Blaire L Osborn; Reese H Clark; Emmanuel B Walter Journal: Pediatr Infect Dis J Date: 2020-03 Impact factor: 3.806
Authors: Leena Choi; Cole Beck; Elizabeth McNeer; Hannah L Weeks; Michael L Williams; Nathan T James; Xinnan Niu; Bassel W Abou-Khalil; Kelly A Birdwell; Dan M Roden; C Michael Stein; Cosmin A Bejan; Joshua C Denny; Sara L Van Driest Journal: Clin Pharmacol Ther Date: 2020-02-11 Impact factor: 6.875